Back to News
Market Impact: 0.25
Arcus Biosciences, Inc. Reports Third-Quarter 2026 Financial Results
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Arcus Biosciences reported third-quarter 2026 revenue of $9 million, down $17 million (about 65%) from $26 million in the same period of 2025. The supplied article attributes the decline to lower related revenues but does not provide further detail.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
RCUS-0.45
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook